drugset / Trial / NCT01455909

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

NCT01455909

Phase 3 Withdrawn Intarcia Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.

Timeline

Start
2013-02
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 60 ug
Comparator Sitagliptin Small molecule 100 mg Oral